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Prostate cancer (PCa) is the second most common cause of cancer death in men in the developed world [@bib0055]. The androgen receptor (AR) controls PCa growth. Previously, studies of the long-term effects (\>3 mo) of medical castration have demonstrated differing transcriptional response following luteinising hormone-releasing hormone (LHRH) analogue and antiandrogens [@bib0060] and have implicated Wnt/β-catenin signalling in castration-resistant PCa [@bib0065]. We used a new drug called degarelix to rapidly decrease testosterone levels and inform the early in vivo response of human PCa to castration.

1. Patients and methods {#sec0005}
=======================

1.1. Study approval {#sec0010}
-------------------

We obtained full ethics approval for all elements of studies [NCT01852864](ctgov:NCT01852864){#intr0005} (REC ref:11/H0311/2) and [NCT00967889](ctgov:NCT00967889){#intr0010} (REC ref:01/4/061).

1.2. Clinical sample collection {#sec0015}
-------------------------------

Twenty-seven patients with high-risk PCa (according to the D'Amico classification) [@bib0070] were administered 240 mg subcutaneous degarelix (donated by Ferring Pharmaceuticals Inc, Parsippany, NJ, USA) 7 d before radical prostatectomy (RP) (Supplementary Fig. 1a). These patients were matched for risk factors (age, serum prostate-specific antigen, tumour grade and stage) with 20 patients undergoing RP without neoadjuvant degarelix (Supplementary Table 1). Study and control patients underwent surgery contemporaneously using standard operative technique, with similar ischemic time before sampling as described [@bib0075]. Serum samples were obtained at 8 [am]{.smallcaps} prior to surgery.

1.3. Assay of androgen levels in body fluids and tissue {#sec0020}
-------------------------------------------------------

Fresh frozen prostate cores were homogenised, and steroids were extracted and quantified by liquid chromatography coupled with tandem mass spectrometry.

1.4. Gene expression profiling {#sec0025}
------------------------------

We hybridised mRNA onto Illumina HumanHT-12 v4 Expression BeadChips (Illumina, San Diego, CA, USA).

1.5. Accession numbers {#sec0030}
----------------------

Study data are deposited in the National Center for Biotechnology Information Gene Expression Omnibus under accession number GSE72920. Expression data were validated for known AR-regulated genes (*KLK3, FASN*), genes found to be AR regulated in our expression data with known AR binding sites in promoter regions [@bib0080] (*FAM129A, KIAA0101, RAB27A*) and genes of biological importance (*AMACR, ESR1*, cyclin D1) by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC).

1.6. Quantitative real-time polymerase chain reaction {#sec0035}
-----------------------------------------------------

We performed RT-PCR in triplicate using SYBR Green and the 7900HT Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).

1.7. Human tissue microarray construction and immunohistochemistry {#sec0040}
------------------------------------------------------------------

PCa samples (index lesion) from 27 patients were identified on the haematoxylin and eosin--stained sections from formalin-fixed paraffin--embedded RP specimens and marked (A.W.). Triplicate 2-mm tumour cores were taken from these areas and re-embedded in human tissue microarray (TMA) paraffin blocks.

We used a BOND-III automated stainer (Leica Biosystems, Buffalo Grove, IL, USA) and Bond Polymer Refine Detection Kit (Leica Biosystems) for IHC. Scoring was by two blinded observers (including A.W.) until consensus was reached. Staining intensity was classified as 0 (none), 1 (weak), 2 (moderate), and 3 (high). For nuclear staining (*ESR1*, Ki-67, and *CCND1*), we used the following modified scoring systems to quantify the number of moderately or intensely staining nuclei as a proportion of all the malignant epithelial cells: *ESR1* and *CCND1* staining (0, no intensely staining positive nuclei; 1, 0.1--10% intensely stained nuclei per core; 2, 10--20% intensely staining nuclei per core; 3, \>20% stained nuclei per core) and Ki-67 staining (0, no positive nuclei; 1, 1--5% positive nuclei; 2, 5--10% positive nuclei; 3, \>10% positive nuclei).

1.8. Statistical analysis {#sec0045}
-------------------------

All data are quoted as median plus or minus interquartile range, and *p* values \<0.05 were considered significant. We use the paired *t* test for paired data; for unpaired data, we used an unpaired *t* test for parametric data and the Mann-Whitney test for nonparametric data. For TMA IHC scoring analysis, we computed the mean intensities for each sample and performed a Mann-Whitney test.

1.9. Gene set enrichment analysis {#sec0050}
---------------------------------

We used Gene Set Enrichment Analysis (GSEA) version 2.0.14 (The Broad Institute, Cambridge, MA, USA). We used the Reactome version 3.0 database to analyse differentially expressed genes (DEGs) following castration for enrichment of predefined gene sets. Using the JASPAR database in the Pscan Web interface (version 1.3), we analysed 500 bases upstream of the top 500 DEGs for enriched transcription factor binding sites ([Fig. 2](#fig0010){ref-type="fig"}C).

2. Results {#sec0055}
==========

We saw no differences in the tumour or patient characteristics of the study and control cohorts (Supplementary Table 1). We saw a rapid decrease in the serum testosterone at 7 d after degarelix administration in all treated patients (11.73 ± 5.08 vs 1.19 ± 0.63 nmol/l) (Supplementary Fig. 1B), paralleled by a decrease in intratumoural androgens (Supplementary Fig. 1C). We identified 749 genes downregulated and 908 genes upregulated in response to castration. Expression levels of known AR-regulated genes---including *TMPRSS2, FKBP5, KLK3*, and *FASN*---were among those most strongly affected by treatment (Supplementary Table 2 and 3). We validated differential expression for eight genes by RT-PCR and IHC ([Fig. 1](#fig0005){ref-type="fig"}B and 1C).

Degarelix treatment decreased nuclear expression of proliferation marker Ki-67 protein and cell cycle progression (expression of nuclear *CCND1*) ([Fig. 1](#fig0005){ref-type="fig"}B and 1C). We observed and validated decreased expression of three genes with limited evidence of AR regulation but with AR binding sites in their promoter regions (*RAB27A, KIAA0101*, and *FAM129A*) following degarelix treatment ([Fig. 1](#fig0005){ref-type="fig"}A--1C)

2.1. ESR1 expression is upregulated in malignant epithelia, is pro-proliferative, and is associated with transcription of known ESR1 target genes {#sec0060}
-------------------------------------------------------------------------------------------------------------------------------------------------

Degarelix treatment upregulated *ESR1* mRNA ([Fig. 2](#fig0010){ref-type="fig"}A). Using GSEA, we demonstrated enrichment of genes that had an *ESR1* binding motif ([Fig. 2](#fig0010){ref-type="fig"}B) [@bib0085] within the promoter region and genes known to be involved in *ESR1* signalling ([Fig. 2](#fig0010){ref-type="fig"}C) among those genes whose expression was upregulated with degarelix treatment ([Fig. 2](#fig0010){ref-type="fig"}C).

IHC demonstrated expression of *ESR1* by stromal cells but not epithelial cells (benign or malignant) in untreated samples, but 24% of degarelix-treated cancers stained positive for *ESR1* in malignant epithelia compared with 8% of untreated samples ([Fig. 2](#fig0010){ref-type="fig"}E). Despite an overall decrease in the expression of the proliferation marker Ki-67 in malignant glands following degarelix treatment ([Fig. 1](#fig0005){ref-type="fig"}B and 1C); in those glands with increased nuclear *ESR1* staining, proliferation was upregulated ([Fig. 2](#fig0010){ref-type="fig"}F).

3. Discussion {#sec0065}
=============

In addition to identifying a large number of AR-regulated genes, we have confirmed AR regulation of three genes (*RAB27A, FAM129*, and *KIAA0101*) not proven to be AR regulated in vivo as well as *AMACR*, for which data were conflicting. *ESR1* is essential for prostate carcinogenesis and implicated in PCa growth control [@bib0090]. Polymorphism of *ESR1* is associated with PCa prognosis [@bib0095].

We observed rapid upregulation of *ESR1* expression with castration ([Fig. 2](#fig0010){ref-type="fig"}A). Increased *ESR1* mRNA expression following prolonged castration using LHRH analogues has been observed [@bib0060], [@bib0065]. Upregulation of *ESR1* expression may represent an intrinsic mechanism by which some malignant prostate epithelial cells proliferate despite castration.
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Appendix A. Supplementary data {#sec0080}
==============================

Supplementary data associated with this article can be found, in the online version, at [http://dx.doi.org/10.1016/j.eururo.2015.10.042](10.1016/j.eururo.2015.10.042){#intr0015}.

![Degarelix treatment regulates expression of known androgen receptor (AR)--regulated genes and genes not previously identified as AR regulated. (A) Messenger RNA expression levels of known AR-regulated genes *PSA* and *FASN* as well as putative AR-regulated genes *AMACR, FAM129A, RAB27A*, and *KIAA0101* were decreased in degarelix-treated (+) prostate cancer (PCa) samples compared with untreated (−) samples. (B) Representative immunohistochemistry (IHC) images of PCa samples from degarelix-treated and untreated patients. Inlay = ×2 magnification. Scale bars = 250 μm. (C) Bar chart to show the distribution of staining intensity of a tissue microarray made up of PCa samples from untreated (−) and degarelix-treated (+) patients stained by IHC (0 \[no staining\] to 3 \[intense staining\]; samples in triplicate; sample sizes \[*n*\] evaluated in each analysis include the number of subjects \[20 or 27\] times 3 minus missing or damaged samples; staining intensity 0 \[none\] to 3 \[strong\]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test).](gr1){#fig0005}

![*ESR1* is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of *ESR1* in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis (GSEA) to examine the distribution of known genes with the *ESR1* binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The *ESR1* binding motif analysed was described previously [@bib0085]. (Bii) This *ESR1* binding motif closely matches the validated, experimentally derived *ESR1* binding motif [@bib0100] shown here. (C) GSEA demonstrates enrichment of factors known to be involved with *ESR1* signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the *normalised enrichment score*, which was 2.036 (false discovery rate *q*-value of 0.027; *p* = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for *ESR1* in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC *ESR1* staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes \[*n*\] indicate the number of subjects \[20 or 27\] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 \[none\] to 3 \[strong\]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for *ESR1* and Ki-67. Spearman\'s ρ correlation coefficient of 0.338 (*p* = 0.041).](gr2){#fig0010}
